Celltrion reported 623.7 billion won ($521 million) in net profit in 2021, up 20.1 percent on year, according to a regulatory filing on Wednesday.
Celltrion said Monday Phase 1 clinical trials of an inhalable form of Regkirona produced meaningful results confirming safety.
Regkirona, Korea’s first Covid-19 treatment, won two-year temporary use authorization from regulators in Switzerland, developer Celltrion said Friday.
Celltrion Healthcare has signed deals for Regkirona, Korea's first Covid-19 treatment, with 18 countries.
Regkirona, Korea’s first Covid-19 treatment, won conditional use approval from regulators in Australia, manufacturer Celltrion said Tuesday.
Celltrion Healthcare has signed agreements with nine European countries for the distribution of Regkirona, Korea's first Covid-19 treatment.
Regkirona, Korea’s first Covid-19 treatment, won conditional use approval from regulators in Peru, Celltrion said Monday.
Regkirona, Korea’s first Covid-19 treatment, won marketing approval from the European Commission, Celltrion said Monday.
Celltrion said Tuesday it applied to the European Medicines Agency (EMA) for a marketing authorization for Regkirona, its Covid-19 treatment.
Celltrion’s Covid-19 treatment Regkirona was approved for use by the Ministry of Food and Drug Safety, the Korean bio company said Friday.
Korea JoongAng Daily Sitemap